Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Octreotide (Sandostatin) Peptide
Synthetic somatostatin analog for acromegaly and neuroendocrine tumors.
What is Octreotide (Sandostatin)?
Octreotide (Sandostatin) is a somatostatin analog · oncology peptide studied for acromegaly and carcinoid syndrome. Below is an educational overview of Octreotide (Sandostatin) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Sandostatin, Sandostatin LAR, Mycapssa (oral)
Acromegaly, carcinoid syndrome flushing/diarrhea, VIPoma watery diarrhea.
A long-acting form of somatostatin that quiets overactive hormone-producing tumors and shrinks GH excess.
- •Diarrhea
- •Abdominal pain/cramping
- •Nausea
- •Gallstones
- •Injection-site pain
- •Gallbladder disease and stones
- •Hyperglycemia or hypoglycemia
- •Slow heart rate / arrhythmia
- •Thyroid suppression
- •Known hypersensitivity to octreotide
- •Untreated gallbladder disease (caution)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Octreotide (Sandostatin) Mechanism of Action
An 8-amino-acid synthetic analog of somatostatin that binds somatostatin receptors (primarily SSTR2 and SSTR5), suppressing growth hormone, glucagon, insulin, and several gastrointestinal hormones. Longer half-life than native somatostatin enables therapeutic use.
Octreotide (Sandostatin) Research Areas & Benefits
Octreotide (Sandostatin) Dosage & Common Research Protocols
Subcutaneous 50–200 mcg 3×/day, or long-acting depot (LAR) monthly IM.
Depot LAR 20–30 mg IM every 4 weeks.
Protocols summarized for educational reference from published research. Not dosing guidance.
Octreotide (Sandostatin) — Frequently Asked Questions
Lanreotide versus octreotide — which has better outcomes?+
Randomized and observational studies in acromegaly and neuroendocrine tumors show broadly equivalent efficacy for lanreotide autogel and octreotide LAR at approved dose ranges — comparable biochemical response, tumor stabilization, and symptom control. Selection is typically driven by injection route (deep SC vs IM), self- or partner-administration preference, and tolerability, not raw efficacy.
Octreotide and lanreotide — are they interchangeable?+
They are the same drug class (somatostatin analogues, SSAs) but not identical drugs. Both bind somatostatin receptors (mainly SSTR2 and SSTR5) with comparable affinity profiles. Published switch protocols exist in both directions, but interchange is a clinical decision — not a like-for-like substitution.
What is the difference between octreotide and lanreotide administration?+
Octreotide LAR is a 6–8 mL intramuscular gluteal injection reconstituted from powder, administered by a healthcare professional. Lanreotide autogel is a pre-filled 0.5 mL deep-subcutaneous injection into the upper outer buttock and can be administered by a trained partner or, in some regions, by the patient.
Octreotide (Sandostatin) Studies & Cited Research
Octreotide LAR in acromegaly
Pivotal trial demonstrating normalization of GH and IGF-1 with monthly depot dosing.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Octreotide (Sandostatin) Side Effects & Safety Considerations
- •FDA-approved.
- •Gallstones, hyperglycemia, GI upset are common adverse effects.
Common questions about Octreotide (Sandostatin)
More Clinical peptides · See all 43
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.